Craig-Hallum Maintains Buy on LifeMD, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alex Fuhrman maintains a Buy rating on LifeMD (NASDAQ:LFMD) and raises the price target from $10 to $15.

March 12, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeMD's Buy rating is maintained by Craig-Hallum, with the price target increased from $10 to $15.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the company's future performance, suggesting potential upside for the stock. This is based on the analyst's research and expectations, which can influence investor sentiment and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100